FDA approves initiation of Phase III clinical trial for nasopharyngeal cancer

Tessa Therapeutics received US Food and Drug Administration (FDA) approval in March 2015 to initiate a Phase III clinical trial involving adoptive EBV-specific T Cell therapy to treat nasopharyngeal cancer. This is the world’s first and largest Phase III T Cell therapy cancer trial. Tessa Therapeutics has an exclusive license to EBV-specific T Cell technology from the National Cancer Centre Singapore (NCCS).